IP Library Granted Patent US 12709752
Granted Patent B2
US 12709752 · App. 19/306,057 · Granted Aug 18, 2026

Compositions and methods for inhibiting XDH expression

Inventors: Allison Cherry Ostriker (Lexington, MA); Martin Lee Koser (Westford, MA)
Assignee: NOVO NORDISK A/S
C12N15/1137C12Y117/01004C12N2310/14C12N2310/315C12N2310/321C12N2310/351
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12709752
App. No.
19/306,057
Granted
Aug 18, 2026
Kind
B2
Abstract

Oligonucleotides are provided herein that inhibit XDH expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with aberrant XDH expression.

Claims (5)

1 . An siRNA comprising a first RNA oligonucleotide and a second RNA oligonucleotide, wherein the first RNA oligonucleotide consists of the sequence set forth in SEQ ID: 23, and the second RNA oligonucleotide consists of the sequence set forth in SEQ ID: 24.

2 . A pharmaceutical composition comprising the siRNA according to claim 1 and a pharmaceutically acceptable carrier, delivery agent or excipient.

3 . A method of treating gout in a subject in need thereof, the method comprising administering to the subject the siRNA of claim 1 .

4 . A method for reducing xanthine dehydrogenase (XDH) expression in a subject in need thereof, the method comprising administering to the subject the siRNA of claim 1 .

5 . A method for reducing XDH expression in a cell, the method comprising contacting the cell with the siRNA of claim 1 .